Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2010 - 2026)
Cumberland Pharmaceuticals' (CPIX) quarterly Interest & Investment Income came in at $78031.0 in Q1 2026, down 37.93% year-on-year from $125709.0 in Q1 2025, and down 15.15% quarter-over-quarter from $91967.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has disclosed Interest & Investment Income across 17 years of filings, most recently posting $78031.0 for Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $78031.0, down 37.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $429070.0 (up 18.07% YoY), and the FY2025 annual result was $476748.0, up 42.55% from the prior year.
- Interest & Investment Income came in at $78031.0 for Q1 2026 at Cumberland Pharmaceuticals, down from $91967.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $131583.0 in Q3 2025 to a low of $15066.0 in Q2 2022.
- The 5-year median for Interest & Investment Income is $78031.0 (2026), against an average of $74969.5.
- Across the five-year window, Interest & Investment Income surged 585.1% in 2022 and sank 37.93% in 2026, its largest moves.
- Cumberland Pharmaceuticals' Interest & Investment Income stood at $45696.0 in 2022, then surged by 77.26% to $81000.0 in 2023, then jumped by 31.69% to $106667.0 in 2024, then declined by 13.78% to $91967.0 in 2025, then slipped by 15.15% to $78031.0 in 2026.
- The last three Interest & Investment Income figures came in at $78031.0 (Q1 2026), $91967.0 (Q4 2025), and $131583.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 41.80 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 28.10 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 8.54 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 4.97 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | Cumberland Pharmaceuticals | 81.83 Mn | 70.49 Mn | 7.20 Mn | 78,031.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78,031.00 |
| Dec 31, 2025 | 91,967.00 |
| Sep 30, 2025 | 131,583.00 |
| Jun 30, 2025 | 127,489.00 |
| Mar 31, 2025 | 125,709.00 |
| Dec 31, 2024 | 106,667.00 |
| Sep 30, 2024 | 69,190.00 |
| Jun 30, 2024 | 61,841.00 |
| Mar 31, 2024 | 96,746.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | 98,603.00 |
| Jun 30, 2023 | 57,061.00 |
| Mar 31, 2023 | 50,190.00 |
| Dec 31, 2022 | 45,696.00 |
| Sep 30, 2022 | 21,602.00 |
| Jun 30, 2022 | 15,066.00 |
| Mar 31, 2022 | 16,041.00 |
| Dec 31, 2021 | 6,670.00 |
| Sep 30, 2021 | 7,394.00 |
| Jun 30, 2021 | 6,591.00 |